Tagged with A

India Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.” DeYoung also touches on what brought him from the world of consulting and private equity to a family-owned Indian pharma…

Morocco Morocco is currently implementing the most ambitious, far-reaching, and comprehensive health system reorganizations in its history. “What sets this reform apart from all that has happened before is just how starkly it differs in spirit from previous incremental and piecemeal initiatives that have been attempted over the decades,” proudly asserts…

Portugal Portugal’s strong legal framework along with its low production costs and strategic location within Europe have given rise to a thriving medicinal cannabis sector. With exports in 2022 that surpassed the previous year by 63 percent and an increasing number of companies licensed for cultivation and manufacturing, the country is…

United Kingdom Since its creation over 20 years ago, the National Institute for Health and Care Excellence (NICE), the Health Technology Assessment (HTA) body for England and Wales, has forged a solid reputation as one of the world’s foremost HTA authorities. Speaking at the recent FT Global Pharma and Biotech Summit, NICE…

Portugal Erstwhile 21-year CEO of leading Portuguese generics group Tecnimede, Maria do Carmo Neves today serves as president of her country’s generics industry association, APOGEN. She outlines the highly challenging market situation facing generics, biosimilar, and value-added medicine producers in Portugal today; how this situation reflects Europe-wide trends; and the solutions…

Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility.   Johnson & Johnson Innovation…

India As secretary general of the Indian Pharmaceutical Alliance (IPA) Sudarshan Jain represents the interests of 25 leading Indian pharmaceutical companies, both at home and abroad. He outlines the association’s focus on quality, innovation, and global reach, why the IPA is aiming to position India as a global benchmark for pharma…

MENA With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the second largest pharma market on the African continent. Recent reforms have also sped up drug approvals and are turning the…

India The IDMA’s Daara Patel outlines the association’s role in representing the diverse voices of the Indian pharmaceutical sector, advocating for manufacturers of all sizes. He explores the challenges and initiatives around aligning with global standards, addressing issues like regulatory complexities and the shift towards biologics. Patel also uncovers the Indian…

Global UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus. Speaking at the recent FT Global Pharma and Biotech Summit, CEO Jean-Christophe Tellier discussed the Belgian midcap’s digital undertakings and…

Germany The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes Pharma’s plans to spend EUR 25 million euros to enhance its production capabilities.   Eli Lilly plans new 2 billion…

USA Nominated by President Joe Biden, the National Institutes of Health’s (NIH) new director Monica M. Bertagnolli took the reins of the world’s largest public funder of biomedical research earlier this month. With a clear focus on improving access and clinical trial diversity, Bertagnolli’s priorities for the role appear to align…